Advertisement


Ethan M. Basch, MD, on Symptom Monitoring: Findings on Overall Survival Rates

2017 ASCO Annual Meeting

Advertisement

Ethan M. Basch, MD, of the University of North Carolina, discusses results from a study that assessed patient-reported outcomes for symptom monitoring during routine cancer treatment of metastatic solid tumors. (Abstract LBA2)



Related Videos

Supportive Care
Issues in Oncology

Gary Rodin, MD, on Advanced Cancer: The CALM Psychological Intervention

Gary Rodin, MD, of the University of Toronto, discusses study findings on a systematic approach to alleviating distress and managing predictable challenges. (Abstract LBA10001)

Hepatobiliary Cancer

Ann-Lii Cheng, MD, PhD, on Hepatocellular Carcinoma: Trial Results on Lenvatinib vs Sorafenib

Ann-Lii Cheng, MD, PhD, of the National Taiwan University Hospital, discusses phase III study findings on lenvatinib vs sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma. (Abstract 4001)

Colorectal Cancer

Axel Grothey, MD, on Colon Cancer: Results of the IDEA Collaboration

Axel Grothey, MD, of the Mayo Clinic Rochester, discusses study findings on shortening the duration of adjuvant oxaliplatin-based therapy, linked to neurotoxicity, for patients with stage III colon cancer. (Abstract LBA1)

Lymphoma

Julie Vose, MD, MBA, on DLBCL and FL: Expert Commentary on Two Studies

Julie Vose, MD, MBA, of the University of Nebraska Medical Center, discusses two hematologic abstracts: results from the OPTIMAL>60 study on radiotherapy to bulky disease PET-negative after immunochemotherapy in elderly patients with diffuse large B-cell lymphoma; and an analysis of autologous vs matched sibling donor or matched unrelated donor allogeneic hematopoietic cell transplantation in follicular lymphoma patients with early chemoimmunotherapy failure. (Abstracts 7506, 7508)

Prostate Cancer

Karim Fizazi, MD, PhD, on Prostate Cancer: Results From the LATITUDE Trial

Karim Fizazi, MD, PhD, of the University Paris-Sud, discusses study findings on androgen-deprivation therapy with abiraterone acetate plus prednisone or placebos in newly diagnosed high-risk metastatic hormone-naive prostate cancer. (Abstract LBA3)

Advertisement

Advertisement




Advertisement